MOZ/TIF2-induced acute myeloid leukaemia in transgenic fish.

Date publication

novembre 2008

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BASTIE Jean-Noël , Pr MARTIN Laurent

Tous les auteurs :
Zhuravleva J, Paggetti J, Martin L, Hammann A, Solary E, Bastie JN, Delva L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/18729850

Résumé

The inv(8)(p11q13) chromosomal abnormality, described in acute myeloid leukaemias (AML), fuses the histone acetyl-transferase (HAT) MYST3 (MOZ) gene with another HAT gene, NCOA2 (TIF2). We generated a transgenic zebrafish in which the MYST3/NCOA2 fusion gene was expressed under control of the spi1 promoter. An AML developed in 2 of 180 MYST3/NCOA2-EGFP-expressing embryos, 14 and 26 months after injection of the fusion gene in a one-cell embryo, respectively. This leukaemia was characterised by an extensive invasion of kidneys by myeloid blast cells. This model, which is the first zebrafish model of AML, demonstrates the oncogenic potency of MYST3/NCOA2 fusion gene.

Référence

Br J Haematol. 2008 Nov;143(3):378-82